Aveo Capital Partners LLC Has $225,000 Position in ARCA biopharma, Inc. (NASDAQ:ABIO)

Aveo Capital Partners LLC increased its stake in shares of ARCA biopharma, Inc. (NASDAQ:ABIO) by 93.7% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 93,667 shares of the biopharmaceutical company’s stock after buying an additional 45,322 shares during the period. Aveo Capital Partners LLC owned approximately 1.01% of ARCA biopharma worth $225,000 at the end of the most recent reporting period.

Shares of ARCA biopharma, Inc. (NASDAQ ABIO) traded up 2.000% during mid-day trading on Friday, hitting $1.275. The stock had a trading volume of 86,575 shares. The firm’s market cap is $14.98 million. ARCA biopharma, Inc. has a 12-month low of $1.13 and a 12-month high of $3.11. The company has a 50 day moving average price of $2.08 and a 200 day moving average price of $2.37.

ARCA biopharma (NASDAQ:ABIO) last released its earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.59) earnings per share (EPS) for the quarter. Equities analysts forecast that ARCA biopharma, Inc. will post ($1.75) earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: This report was originally published by Rincon Hill News and is the sole property of of Rincon Hill News. If you are reading this report on another domain, it was copied illegally and reposted in violation of international trademark & copyright laws. The correct version of this report can be read at https://rinconhillneighbors.org/2017/08/19/aveo-capital-partners-llc-buys-45322-shares-of-arca-biopharma-inc-nasdaqabio-updated.html.

ARCA biopharma Company Profile

ARCA biopharma, Inc (ARCA) is a biopharmaceutical company. The Company is principally focused on developing genetically-targeted therapies for cardiovascular diseases. The Company’s lead product candidate is Gencaro (bucindolol hydrochloride), a beta-blocker and mild vasodilator that the Company is evaluating in a clinical trial for the treatment of atrial fibrillation (AF) in patients with heart failure with reduced left ventricular ejection fraction (HFREF).

Receive News & Ratings for ARCA biopharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ARCA biopharma Inc. and related companies with our FREE daily email newsletter.

 

Latest News



Leave a Reply

 
© 2006-2017 Rincon Hill News.